Septic shock management has undergone significant evidence-based evolution over the past decade — with the early goal-directed therapy (EGDT) paradigm from Rivers et al. (2001) largely abandoned after the ProCESS, ARISE, and ProMISe trials showed no mortality benefit over usual care, and with refined understanding of fluid, vasopressor, and adjunctive therapy selection. The Surviving Sepsis Campaign guidelines (2021 update) and subsequent RCT evidence guide current practice.
Fluid Resuscitation: The SMART Trial and Beyond
The Saline vs. Lactated Ringer's vs. Plasmalyte (SMART) trial (2018, NEJM, n=15,802 ICU patients) and the SALT-ED trial established balanced crystalloids (lactated Ringer's, Plasmalyte) as superior to normal saline for critically ill patients — saline produces hyperchloremic metabolic acidosis and is associated with higher rates of major adverse kidney events (MAKE30). Current guidance: balanced crystalloids preferred over normal saline for septic shock resuscitation. The 30mL/kg initial bolus: the SSC Hour-1 Bundle requires 30mL/kg crystalloid within 1 hour for hypotension or lactate ≥4mmol/L. Evidence controversy: CLOVERS trial (2023) and PLUS trial did not show mortality benefit from more liberal fluid strategies — and the CLOVERS liberal fluid protocol did not reduce organ failure versus restrictive strategy. Current best practice: 30mL/kg initial resuscitation, then reassess with dynamic measures (pulse pressure variation, straight leg raise) rather than fixed-volume protocols. Albumin: SAFE trial showed no mortality benefit over saline overall, but subgroup analysis suggested possible benefit in sepsis; ALBIOS trial found no benefit from albumin supplementation to target albumin ≥30g/L.
Vasopressors and Adjunctive Therapies
Norepinephrine remains first-line vasopressor for septic shock — CATS meta-analysis confirmed superiority over dopamine (lower 28-day mortality, fewer arrhythmias). Vasopressin addition: VASST trial showed vasopressin 0.03 units/min added to norepinephrine reduces norepinephrine requirements without mortality benefit in the overall group — but significant benefit in less severe septic shock (norepinephrine 0.1–0.2 mcg/kg/min subgroup). Corticosteroids: APROCCHSS trial (2018): hydrocortisone + fludrocortisone significantly reduced 90-day mortality (43% vs. 49%) in catecholamine-refractory septic shock. SSC guidelines recommend hydrocortisone 200mg/day IV when shock is refractory to vasopressors. For ICU and critical care facilities managing septic shock, our IV vascular access catalog includes central line kits, IV tubing, and infusion supplies essential for septic shock resuscitation, and our PPE section ensures proper infection control during sepsis management.
